- Market Overview
- Futures
- Options
- Custom Charts
- Spread Charts
- Market Heat Maps
- Historical Data
- Stocks
- Real-Time Markets
- Site Register
- Mobile Website
- Trading Calendar
- Futures 101
- Commodity Symbols
- Real-Time Quotes
- CME Resource Center
- Farmer's Almanac
- USDA Reports
Labcorp Holdings Stock Outlook: Is Wall Street Bullish or Bearish?
/Labcorp%20Holdings%20Inc_%20location-by%20Sundry%20Photography%20via%20iStock.jpg)
With a market cap of $20.3 billion, Labcorp Holdings Inc. (LH) is a leading healthcare diagnostics company offering a broad range of clinical laboratory and drug development services. Through its Diagnostics Laboratories and Biopharma Laboratory Services segments, Labcorp supports healthcare providers, pharmaceutical companies, and patients with critical testing, research, and diagnostic solutions.
Shares of the Burlington, North Carolina-based company have outperformed the broader market over the past 52 weeks. LH has increased 23.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 10.2%. Moreover, Labcorp stock has risen 5.8% on a YTD basis, compared to SPX's 1.3% decline.
Looking closer, the medical laboratory operator has also outpaced the Health Care Select Sector SPDR Fund's (XLV) 10.1% decrease over the past 52 weeks.
Despite reporting weaker-than-expected Q1 2025 revenue of $3.4 billion, Labcorp shares rose 4.7% on Apr. 29. The company posted adjusted EPS of $3.84, beating the consensus estimate, driven by 6% growth in its Diagnostics Laboratories business to $2.6 billion. Investor sentiment was further boosted by healthy demand for non-urgent surgeries and checkups, particularly among older Americans, and ongoing growth from hospital lab management deals. Additionally, Labcorp raised the lower end of its full-year adjusted profit forecast to $15.70.
For the fiscal year ending in December 2025, analysts expect LH’s adjusted EPS to grow 10.2% year-over-year to $16.05. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters.
Among the 17 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 14 “Strong Buy” ratings and three “Holds.”
This configuration is more bullish than three months ago, with 12 “Strong Buy” ratings on the stock.
On May 12, Truist analyst David MacDonald raised Labcorp’s price target to $290 and maintained a “Buy" rating, citing updated models based on Q1 results and revised guidance.
As of writing, LH is trading below the mean price target of $276.47. The Street-high price target of $300 implies a modest potential upside of 23.7% from the current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.